⚠️ No article content returned.
Astrazeneca PLC (AZN)
- Written by: Madison Wilson
Latest Company News
AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in combination with ADCs. The companies will also collaborate on trials combining ivonescimab with Sone-Ve across gastrointestinal cancers.
The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose asthma is inadequately controlled with medium-dose ICS/LABA therapy.
The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised myasthenia gravis, based on Phase III PREVAIL trial results.
The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.
AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.
AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.
